Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …

Background After a median follow-up of 18· 3 months, the third-generation anaplastic
lymphoma kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free …

Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …

The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …